このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

青少年(12 -

2026年10月14日 更新者:Novartis Pharmaceuticals

H1-抗ヒスタミン薬によるコントロールが不十分な慢性自然蕁麻疹を有する 12 歳から 18 歳未満の青年における 24 週間のレミブルチニブ (LOU064) の有効性、薬物動態および安全性を評価するための二重盲検無作為化プラセボ対照試験さらに 3 年間のオプションの非盲検延長と、追加の 3 年間のオプションの長期無治療フォローアップ期間

The purpose of this trial is:

  1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
  2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
  3. to collect safety data in this population for up to three years after the last dose of study treatment

調査の概要

状態

積極的、募集していない

詳細な説明

This trial consists of 3 different periods:

  1. the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
  2. an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
  3. an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.

The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment

研究の種類

介入

入学 (実際)

100

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Bakersfield、California、アメリカ、93301
        • Kern Research
      • San Diego、California、アメリカ、92123
        • Allergy and Asthma Medical Group and Research Center
    • Florida
      • Miami、Florida、アメリカ、33156
        • Pediatric Dermatology of Miami at the Pediatric CoE
    • Idaho
      • Boise、Idaho、アメリカ、83706
        • Treasure Valley Medical Research
    • Illinois
      • Glenview、Illinois、アメリカ、60077
        • Endeavor Health
    • Kentucky
      • Owensboro、Kentucky、アメリカ、42301
        • Allergy and Asthma Specialist P S C
    • Ohio
      • Toledo、Ohio、アメリカ、43617
        • Toledo Institute of Clinical Research
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73120
        • Allergy Asthma and Clinical Research
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15241
        • Allergy and Clinical Immunology Associates
    • Texas
      • San Antonio、Texas、アメリカ、78213
        • RFSA Dermatology
    • Utah
      • Sandy City、Utah、アメリカ、84093
        • Allergy Associates of Utah
      • CABA、アルゼンチン、C1181ACH
        • Novartis Investigative Site
      • San Miguel de Tucumán、アルゼンチン、T4000AXL
        • Novartis Investigative Site
    • Buenos Aires
      • CABA、Buenos Aires、アルゼンチン、C1414AIF
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario、Santa Fe Province、アルゼンチン、S2000DEJ
        • Novartis Investigative Site
      • Manchester、イギリス、M13 9WL
        • Novartis Investigative Site
      • Southampton、イギリス、SO16 6YD
        • Novartis Investigative Site
    • Cambridgeshire
      • Peterborough、Cambridgeshire、イギリス、PE3 9GZ
        • Novartis Investigative Site
    • FI
      • Florence、FI、イタリア、50139
        • Novartis Investigative Site
    • PV
      • Pavia、PV、イタリア、27100
        • Novartis Investigative Site
    • SI
      • Siena、SI、イタリア、53100
        • Novartis Investigative Site
      • Utrecht、オランダ、3584 CX
        • Novartis Investigative Site
    • Quebec
      • Montreal、Quebec、カナダ、H4A 3J1
        • Novartis Investigative Site
      • Valencia、スペイン、46014
        • Novartis Investigative Site
    • Barcelona
      • Esplugues、Barcelona、スペイン、08950
        • Novartis Investigative Site
      • Bangkok、タイ、10330
        • Novartis Investigative Site
      • Bangkok、タイ、10700
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla、Hat Yai、タイ、90110
        • Novartis Investigative Site
    • Santiago Metropolitan
      • Santiago、Santiago Metropolitan、チリ、8420383
        • Novartis Investigative Site
      • Adana、トルコ(Türkiye)、01330
        • Novartis Investigative Site
    • Fatih
      • Istanbul、Fatih、トルコ(Türkiye)、34093
        • Novartis Investigative Site
    • Sihhiye Altindag
      • Ankara、Sihhiye Altindag、トルコ(Türkiye)、06230
        • Novartis Investigative Site
      • Berlin、ドイツ、13353
        • Novartis Investigative Site
      • Tübingen、ドイツ、72076
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main、Hesse、ドイツ、60590
        • Novartis Investigative Site
      • Lodz、ポーランド、90-436
        • Novartis Investigative Site
    • Sarawak
      • Kuching、Sarawak、マレーシア、93586
        • Novartis Investigative Site
      • Beijing、中国、100050
        • Novartis Investigative Site
      • Beijing、中国、100069
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou、Guangdong、中国、510091
        • Novartis Investigative Site
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • Novartis Investigative Site
      • Cape Town、南アフリカ、7925
        • Novartis Investigative Site
    • Gauteng
      • Pretoria、Gauteng、南アフリカ、0181
        • Novartis Investigative Site
    • Fukuoka
      • Kitakyushu、Fukuoka、日本、8078556
        • Novartis Investigative Site
    • Kumamoto
      • Kamimashi-gun、Kumamoto、日本、8613106
        • Novartis Investigative Site
    • Osaka
      • Sakai、Osaka、日本、5938324
        • Novartis Investigative Site
    • Shimane
      • Izumo、Shimane、日本、6938501
        • Novartis Investigative Site
    • Tokyo
      • tabashi City、Tokyo、日本、1738610
        • Novartis Investigative Site
    • Hong Kong
      • Hong Kong、Hong Kong、香港、999077
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年~17年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  • Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
  • Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
  • The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
  • UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
  • Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)

Key Exclusion criteria:

  • Previous use of remibrutinib or other BTK inhibitors
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding
  • Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
  • History or current hepatic disease
  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
  • History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
  • Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis

Other protocol-defined inclusion/exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1: LOU064 (blinded)

LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.

LOU064 (blinded) active treatment

他の名前:
  • レミブルチニブ
プラセボコンパレーター:Arm 2: LOU064 placebo (blinded)

LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)

matching active drug

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from baseline in UAS7
時間枠:Baseline, week 12

The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0.

Negative change from baseline indicates improvement.

Baseline, week 12
Change fron baseline in ISS7
時間枠:Baseline, Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline, Week 12
Change from baseline in HSS7
時間枠:Baseline, Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline, Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Cmax of remibrutinib
時間枠:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The maximum (peak) observed blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Tmax of remibrutinib
時間枠:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The time to reach maximum (peak) blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
AUClast of remibrutinib
時間枠:At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Absolute change from baseline in ISS7
時間枠:Baseline - Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline - Week 12
Absolute change from baseline in HSS7
時間枠:Baseline - Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline - Week 12
Achievement of UAS7 ≤ 6 (yes/no)
時間枠:Week 12 and over time

Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Achievement of UAS7 = 0 (yes/no)
時間枠:Week 12 and over time

Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Absolute change from baseline in CDLQI score
時間枠:Week 12

The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Week 12
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
時間枠:baseline - Week 12

Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity.

baseline - Week 12
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
時間枠:28 weeks

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study.

28 weeks
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
時間枠:3 years

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study.

3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年7月11日

一次修了 (推定)

2026年11月3日

研究の完了 (推定)

2032年3月30日

試験登録日

最初に提出

2022年12月16日

QC基準を満たした最初の提出物

2022年12月23日

最初の投稿 (実際)

2023年1月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月15日

QC基準を満たした最後の更新が送信されました

2026年10月14日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する